Clinical trial · Observational
Antiangiogenic Factors in Gastric Cancer
The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression
NCT00735566CI-TRIAL-00008299completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Endogenous antiangiogenic factors are related with gastric cancer progression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Relationship between antiangiogenic factor and tumor, node, metastasis
- timeFrame
- One year
Secondary outcomes (1)
- measure
- Overall survival, treatment failure
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic diagnosis of gastric adenocarcinoma * No other forms of cancer therapy, such as chemotherapy or radiotherapy for at least 3 weeks before the enrollment in study * Performance status of 0, 1, 2 on the ECOG criteria * ASA class I, II * Patient compliance that allow adequate follow up * Informed consent from patient or patient's relative. Exclusion Criteria: * Second primary malignancy * EMR (Endoscopic mucosal resection) indication * Laparoscopic gastrectomy * Radiologic or clinical evidence of metastasis
References
Publications (0)
Data not yet available
No reference posted for this study.